Loading data for ABUS — first visit, this takes a few seconds.
Arbutus Biopharma Corporation
5.12 +0.00 (0.00%)
5.14 +0.42%
- Ринкова капіталізація
- $1.01B
- Обсяг торгів
- 1.85M
- Наступна дата звітності
- Nov 16, 2026
Arbutus Biopharma Corporation (ABUS): ціна акції, аналіз і дані
Внутрішня вартість
Прогноз аналітиків
Прогнози по акціях →Останні результати
| Факт | До прогнозу | Зміна р/р | |
|---|---|---|---|
| Виручка | $179.1M | n/a | +10054.54% |
| EPS | -$0.04 | -$0.01 | -500.00% |
Показники
- Купівля
- 3.68
- Ринкова капіталізація
- 1.01B
- Виручка (ttm)
- 182M
- Чистий прибуток (ttm)
- 153M
- 0.62
- 0.79
- 6.48
- -30.98
- P/B (ttm)
- 3.91
- P/S (ttm)
- 5.58
- Дата звіту
- Nov 16, 2026
- Продаж
- 5.13
- Обсяг торгів
- 1,850,049
- Сер. обсяг (20 дн.)
- 3,097,398
- Відкриття
- 5.17
- Попереднє закриття
- 5.12
- Діапазон дня
- 5.11 - 5.17
- Діапазон за 52 тижні
- 3.50 - 5.45
- Аналітик
- n/a
- Цільова ціна
- n/a
- Дивіденди
- n/a
- Екс-дивідендна дата
- n/a
Про Arbutus Biopharma Corporation
Профіль →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Галузь Biotechnology
Сектор Healthcare
Дата IPO Jul 26, 2007
Працівники 19
Біржа NasdaqGS
Тікер ABUS